What is the Zacks forecast for CRISPR Therapeutics AG (CRSP)?
The Zacks forecast for CRISPR Therapeutics AG anticipates a quarterly loss of approximately $1.10 per share for the upcoming earnings report, marking a notable year-over-year improvement compared to previous historical periods. Analysts tracking the genomic medicine pioneer project significant revenue growth, estimating quarterly revenues to reach approximately $7.42 million. Furthermore, the company holds an Earnings ESP (Expected Surprise Prediction) of positive 1.94 percent alongside a Zacks Rank of number 3, indicating that consensus estimates point toward a strong likelihood of meeting or beating expectations as commercialization efforts for its breakthrough gene-editing therapies continue to progress.
Related FAQs
CRSP is the ticker symbol for CRISPR Therapeutics AG, a leading biotechnology company that is at the forefront of the gene-editing revolution.
While CRISPR-Cas9 remains a cornerstone gene-editing technology, next-generation genetic engineering tools such as base editing, prime editing, and epigenetic editing are advancing rapidly to complement or replace standard double-stranded DNA cutt...
Jeff Bezos has directed substantial private capital and strategic investment toward groundbreaking technological frontiers, most notably in commercial space exploration through Blue Origin, artificial intelligence advancements, and life sciences r...
Investing in gene-editing and CRISPR biotechnology equities requires focusing on companies with advanced clinical pipelines, validated therapeutic platforms, and strong institutional partnerships.
Evaluating the five-year stock trajectory of major gene-editing companies requires analyzing clinical trial progression, intellectual property licensing agreements, and the path toward commercial revenue generation from revolutionary CRISPR-based ...
As of July 2026, while CRISPR Therapeutics holds a Buy consensus rating among market professionals, it is not universally categorized as a Strong Buy.
CRISPR Therapeutics AG (CRSP) is a pioneering clinical-stage biopharmaceutical company focused on developing revolutionary gene-editing therapies utilizing CRISPR/Cas9 technology to treat serious genetic diseases.
As of March 2026, the Bill & Melinda Gates Foundation launched a challenge to accelerate charitable giving through AI.
Cirrus Logic (CRUS) operates as a fabless semiconductor designer specializing in high-performance low-power audio and mixed-signal IC solutions, positioning it uniquely against larger diversified chipmakers.
CRISPR Therapeutics, trading under the ticker CRSP, currently maintains a Buy consensus rating among Wall Street analysts as of July 2026.
Diseases that are classified as completely genetic are caused directly by mutations or alterations in a single specific gene, known as monogenic or Mendelian disorders.
Diseases or traits inherited exclusively through the father are linked directly to genetic material residing on the Y chromosome, since fathers pass their single Y chromosome down solely to their biological sons.
Genetic disorders stem from abnormalities or mutations within an individual's DNA sequence, affecting cellular functions and physiological development.
Investing in biotechnology companies utilizing CRISPR gene-editing technology involves navigating high-risk clinical development and scientific uncertainties.
Yes, Cathie Wood’s ARK Invest maintains a position in GitLab Inc. (GTLB) within its portfolio.